At PhalconBio, we are addressing the urgent issue of antibiotic resistance by developing next-generation antibacterial therapies. Our cutting-edge phage therapy platform enhances treatment effectiveness, reduces drug resistance, and provides highly targeted solutions. 

Our primary focus is on treating pulmonary Pseudomonas aeruginosa infections, which are associated with chronic lung conditions as well as hospital-acquired pneumonia. Our adaptable platform allows us to expand our solutions to other critical ESKAPEE pathogens, setting a new standard in precision antibacterial treatments.

PhalconBio

Org chart

Teams

Offices